The latest cardiology practice-changing scientific breakthrough, late-breaking study presentations have been announced for the 2022 American College of Cardiology (ACC) meeting. Top experts will debate and discuss the outcomes of leading-edge trials at ACC.22 and explain how it all fits into current cardiology practice. There are five late-breaking clinical trial sessions, three featured clinical research sessions, and two late-breaking clinical trials (LBCT) deep dive sessions to help cardiologists stay up-to-date on the newest clinical research.
Search the sessions at virtual ACC.22 meeting at https://accscientificsession.acc.org/Plan-Your-Program/Education-Sessions
Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials
Saturday, April 2, 9:30 – 10:30 a.m. ET
VALOR-HCM: Mavacamten as An Alternative to Surgical Septal Myectomy or Alcohol Ablation in Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy
SODIUM-HF: Study of Dietary Intervention Under 100 Mmol in Heart Failure
The POISE-3 Trial: Efficacy and Safety of Tranexamic Acid in Patients Undergoing Noncardiac Surgery
CHAP Trial: Antihypertensive Therapy For Mild Chronic Hypertension Improves Pregnancy Outcomes: A Pragmatic Multicenter RCT
ACC Featured Clinical Research I
Saturday, April 2, 11 a.m. – 12:15 p.m. ET
SCORED Trial: Sotagliflozin Significantly Reduces Cardiovascular Death, Myocardial Infarction, and Stroke in the Scored Trial
Bentracimab Immediately and Significantly Reverses the Antiplatelet Effects of Ticagrelor in Older People
COMPLETE: Effects of Complete Revascularization on Angina-related Quality of Life in Patients With St-segment Elevation Myocardial Infarction
The FAME 3 Trial: Quality of Life After Fractional Flow Reserve-guided Stenting Compared With Coronary Bypass Surgery
Results of the EDIT-CMD Randomized Clinical Trial: Efficacy of Diltiazem to Improve Coronary Vasomotor Dysfunction in Angina and Nonobstructive Coronary Arteries
Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials
Sunday, April 3, 8 – 9:15 a.m. ET
MITIGATE: A Pragmatic Randomized Trial of Icosapent Ethyl for High Cardiovascular Risk Adults in an Era of Coronavirus Disease 2019
TRANSLATE-TIMI 70: Effect of Vupanorsen on Non-high-density Lipoprotein Cholesterol Levels In Statin-treated Patients With Elevated Cholesterol
PACMAN AMI: Effects of Alirocumab on Coronary Atherosclerosis Assessed by Serial Multimodality Intracoronary Imaging in Patients With Acute Myocardial Infarction: A Double-blind, Placebo-controlled, Randomized Trial
APOLLO Trial: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial
SuperWIN: A Multisite, Randomized, Controlled Trial of a Supermarket and Web-based Intervention Targeting Nutrition For Cardiovascular Risk Reduction
Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials
Sunday, April 3, 9:45 – 11 a.m. ET
IVVE: Randomized Controlled Trial of Influenza Vaccine in Patients With Heart Failure to Reduce Adverse Vascular Events
METEORIC-HF: The Effect of Omecamtiv Mecarbil on Exercise Tolerance in Patients With Chronic Heart Failure and Reduced Ejection Fraction
PROMPT-HF: A Cluster-Randomized PRagmatic Trial Aimed at ImprOving Use of Guideline Directed Medical Therapy in OutPatienTs With Heart Failure
DIAMOND Trial: Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-angiotensin-aldosterone System Inhibitor Medications For Heart Failure With Reduced Ejection Fraction
Updated Cumulative Results of Treatment With Mavacamten From the EXPLORER-LTE Cohort of the MAVA-LTE Study in Patients With Obstructive Hypertrophic Cardiomyopathy
Featured Clinical Research II
Sunday, April 3, 12:15 – 1:30 p.m. ET
PACIFIC AF: Multicenter, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel Group, Dose-finding Phase 2 Study Comparing the Safety of the Oral FXIa Inhibitor Asundexian With Apixaban in Patients With Atrial Fibrillation
Residual Leaks Post Left Atrial Appendage Occlusion
A Report From the mAFA-II Trial Long-term Extension Cohort: Consumer-led Screening For Atrial Fibrillation
Results From the PARTITA Trial: Catheter Ablation of Ventricular Tachycardia After the First Implantable Cardioverter Shock
Low Rates of Guideline Directed Care Associated With Higher Mortality in Patients With Infections of Pacemakers and Implantable Cardioverter Defibrillators
Late-Breaking Clinical Trials Deep Dive I
Sunday, April 3, 2 – 3:15 p.m. ET
Get even more insights from key clinical trials presented at ACC.22 and find out what it all means for your patients.
Late-Breaking Clinical Trials IV
Monday, April 4, 8:30 – 9:45 a.m. ET
The PROTECT Trial: Very Mild Perioperative Hypothermia Versus Aggressive Warming and Myocardial Injury After Non-cardiac Surgery
POISE-3: The Effects of a Hypotension-avoidance Strategy Versus a Hypertension-avoidance Strategy In Patients Undergoing Noncardiac Surgery
One-year Results of the Clasp TR Study: Transcatheter Treatment of Tricuspid Regurgitation
Insights From the Corevalve US Pivotal and SURTAVI Trials: Five-year Incidence, Timing and Predictors of Hemodynamic Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses
A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis and Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement
Late-Breaking Clinical Trials V
Monday, April 4, 11 a.m. – 12:15 p.m. ET
GHATI: Improving STEMI Management Internationally: Two-year Report of 4,015 Patients Enrolled in the American College of Cardiology - Global Heart Attack Treatment Initiative
The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis
GIPS-IV: The Groningen Intervention Study For the Preservation of Cardiac Function With Sodium Thiosulfate After St-segment Elevation Myocardial Infarction
BIO|GUARD-MI: The Clinical Effect of Arrhythmia Monitoring After Myocardial Infarction
Featured Clinical Research III
Monday, April 4, 12:45 – 2 p.m. ET
3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications
Fidelity Analyses: Finerenone and Cardiorenal Outcomes by History of Cardiovascular Disease in Patients With Type 2 Diabetes
Secondary Analysis of the CANTOS Trial: Differential Impact of Residual Inflammatory Risk and Residual Cholesterol Risk Among Atherosclerosis Patients With and Without Chronic Kidney Disease
Trends and Final Results of the North American Covid-19 Myocardial Infarction (NACMI) Registry
Results From the EMPULSE Trial: Effects of Empagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients Hospitalized For Acute Heart Failure
Late-Breaking Clinical Trials Deep Dive II
Monday, April 4, 2:30 – 3:45 p.m. ET
Get even more insights from key clinical trials presented at ACC.22 and find out what it all means for your patients.
Keynote Speakers Announced for ACC 2022
Find more news from ACC
April 11, 2024 
